The Journal of Heart and Lung Transplantation 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Genome-Wide Molecular Analysis of Heart Transplant Endomyocardial Biopsies Separately Analyzing Rejection and Parenchymal Injury
Purpose: The Molecular Microscope ® Diagnostic System (MMDx) system for interpreting heart transplant endomyocardial biopsies (EMBs) currently uses expression of kidney-derived rejection-associated transcripts (RATs) to identify antibody-mediated and T cell-mediated rejection (ABMR, TCMR), but this also detects recent acute injury. We developed a new model to assess rejection and injury separately. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , K.S. Madill-Thomsen, M. Mackova, A.Z. Aliabadi-Zuckermann, M. Cadeiras, M. Crespo-Leiro, M. Deng, J. Goekler, S. Hall, A. Jamil, D.H. Kim, J. Kobashigawa, P. MacDonald, J. Patel, L. Potena, K. Shah, J. Stehlik, A. Zuckermann Source Type: research
Concomitant Cell-Free DNA and Donor Specific Antibodies: Do They Predict Outcomes After Heart Transplant?
Purpose: The endomyocardial biopsy is the gold standard to detect rejection after heart transplant (HTx), though non-invasive methods to detect rejection are available, including donor-derived cell-free DNA (dd-cfDNA) and donor specific antibodies (DSA). dd-cfDNA indicates donor heart injury, whereas development of DSA indicates immune system upregulation. The additive prediction of these biomarkers has not been established. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , M. Kittleson, E. Kransdorf, A. Velleca, N. Bhatnagar, A. Kanungo, M. Lee, J. Kermanshahchi, L. Czer, R. Cole, F. Esmailian, J. Kobashigawa Source Type: research
Favorable Use of Daratumumab in Highly Sensitized Pediatric Heart Transplant Candidates and Recipients
We present 3 cases that highlight its favorable use. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , L.C. Reardon, N.J. Halnon, R.S. Khan, A. Fan, M.M. Si, R.M. Biniwale, J.C. Alejos Source Type: research
Ruxolitinib Prevents Pulmonary Function Decline Due to CLAD-BOS in an Adolescent Lung Transplant Recipient
Introduction: Ruxolitinib, an oral Janus-associated kinase 1 and 2 inhibitor, is approved for treatment of chronic graft versus host disease (cGVHD) in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Notably, ruxolitinib has shown promise as a therapy for bronchiolitis obliterans syndrome (BOS) after HSCT leading to improvement in pulmonary function. However, it has not been reported for treatment of BOS phenotype chronic lung allograft dysfunction (CLAD) after lung transplantation. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , J. Simpson, D. Hayes Source Type: research
Absent Sounds: Use of Haptic Devices for LVAD Alarms in a Patient with Hearing Loss
Introduction: The HeartMate 3 (HM3, Abbott, USA) left ventricular assist device (LVAD) is a cornerstone in the management of end-stage heart failure. The device uses audible alarms to signal potential issues to both patients and providers. This methodology for life-threatening alerts poses a challenge for those with significant hearing impairment. Herein, we describe a case of successful HM3 implant in a patient with hearing loss. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , M. Thomas, F. Hussain, S. Garg, J.T. Thibodeau, R. Morlend, E.A. Hardin, C. Wrobel, J. Nixon, M. Peltz, M. Farr Source Type: research
Case Report: A Pulmonary and Peripheral Arteriovenous Malformation in a Pulmonary Hypertension Patient with an Underlying BMPR2 Mutation
Introduction: BMPR2 mutations, accountable for 75-80% of heritable pulmonary hypertension (hPAH) cases, have been associated with the development of pulmonary arteriovenous malformations (pAVM). To date, there have been no documented cases of AVMs in the systemic circulation (sAVM) in patients with BMPR2 mutations. This case report presents a unique case of a patient with a BMPR2 mutation who developed multiple AVMs, not only in the lungs but also at an extrapulmonary site. These findings may hint toward systemic implications of the BMPR2 mutation. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , G. Aerts, L. Willems, J. Verhaegen, G. Maleux, T. Verbelen, B. Vanaudenaerde, L. Ceulemans, R. Vos, C. Belge, R. Quarck, M. Delcroix, L. Godinas Source Type: research
The Impact of Genetic Polymorphism on Complications Development in Heart Failure Patients
Purpose: Congestive heart failure (HF) is a heterogeneous life-threatening syndrome. Heart transplantation (HT) is one of the gold standard treatment at the end-stage of HF. On the other hand, implantation of the mechanical circulatory support (MCS) device is an alternative treatment which improves patient ’s quality of life. However, HF patients have development of the thrombosis and bleeding complications due to the non-physiologic shear-stress and incorrect dosage of antiplatelet drugs. The aim of our research was to identify influence of UGT1A6 gene polymorphism and its impact on the development of the complications ...
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , S. Rakhimova, S. Andosova, S. Akilzhanova, A. Chinybayeva, M. Bekbosynova, A. Akilzhanova Source Type: research
Impact of Vitamin K Antagonist Therapy on Outcomes in a Randomized Controlled Trial of Aspirin Removal in Left Ventricular Assist Device Patients - A Pre-Specified Analysis from The ARIES Trial
Purpose: ARIES is an international, placebo-controlled study of aspirin (100mg daily) in HM3 LVAD patients to test the hypothesis that elimination of aspirin from the anti-thrombotic regimen preserves safety and efficacy and reduces residual risk conferred by non-surgical bleeding complications. The primary endpoint results of the ARIES HM3 Trial will be presented in November 2023. In this pre-specified secondary analysis, we seek to analyze the impact of background vitamin K antagonist (VKA) therapy on hemocompatibility related outcomes. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , M.R. Mehra Source Type: research
Prevalence and Outcomes of Reduced Intensity Anticoagulation in Patients Supported with Left Ventricular Assist Devices
Purpose: Patients with ventricular assist devices (VAD) are typically treated with aspirin and warfarin, but some cannot tolerate full anticoagulation (AC). With the improved biocompatibility observed with a fully magnetically levitated centrifugal flow pump (HeartMate 3 [HM3] VAD), clinicians have more flexibility to reduce AC, reducing bleeding risk. However, limited information exists regarding outcomes in patients on reduced or no AC. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , S. Shin, Q. Huang, S. Sudat, B. Sheridan Source Type: research
A Single-Center Experience with Delayed Heparin Initiation Following Heartmate3 Implantation
Purpose: Anticoagulation (AC) following LVAD implantation is crucial for averting pump thrombosis and thromboembolism. However, balancing thrombotic risk with postoperative bleeding remains a clinical challenge. Despite data suggesting significantly lower rates of pump thrombosis in Heartmate3 (HM3) as compared to the older pumps, contemporary perioperative AC guidelines for HM3 have not changed to reflect this data. We hypothesized that a more conservative HM3 AC protocol would not increase pump thrombosis and reduce peri-operative bleeding. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , M. Thomas, L. Truby, C. Wrobel, D. Varghese, M. Edwards, M. Farr, M. Peltz Source Type: research
A Comprehensive Analysis of Bleeding Outcomes with Aspirin Removal with a Fully Magnetically Levitated LVAD - The International Randomized Controlled ARIES Trial
Purpose: Although hemocompatibility related adverse events including pump thrombosis and stroke have been reduced with introduction of a fully magnetically levitated LVAD, the incidence of non-surgical bleeding remains high. Whether aspirin, as part of an antithrombotic regimen including Vitamin-K Antagonist (VKA) may be safely removed and if it reduces the residual risk of non-surgical bleeding complications remains unknown. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , M.R. Mehra Source Type: research
The cGAS-Sting Pathway Drives Alveolar Epithelial Cell Death via Non-Canonical PKR Signaling During Lung Ischemia-Reperfusion Injury
Purpose: The cGAS-STING pathway, a critical component of cytosolic DNA sensing, plays a pivotal role in regulating inflammation-related diseases. Our study aims to investigate the involvement of the cGAS-STING pathway and its regulatory mechanism in lung ischemia-reperfusion injury (LIRI), providing novel insights into potential therapeutic targets for primary graft dysfunction (PGD). (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , C. Li, H. Liu, C. Chen, J. Wu Source Type: research
Early Post-Transplant Airway Il-5 and Eosinophilia Are Associated with Baseline Lung Allograft Dysfunction and Impaired Allograft Survival
Purpose: Baseline lung allograft dysfunction (BLAD) has been recently described as the failure to attain normal lung function post-lung transplantation. Among bilateral lung transplant recipients (LTRs), BLAD within the first-year post-transplant (Tx) has been associated with impaired survival; however, the pathophysiology of BLAD remains poorly understood. Herein, we compared early airway inflammatory mediators between LTRs with and without BLAD at 1-year post-Tx; this pointed us specifically to airway IL-5 and allograft eosinophilia as risk factors for BLAD. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , C. Camillo, M. Leiva-Juarez, X. Zhou, L. Benvenuto, S. Arcasoy, S. Keshavjee, E. Huszti, A. Sage, F. D'Ovidio, T. Martinu Source Type: research
Early Posttransplant Bronchoalveolar Lavage Fluid (BALF) Hyaluronan is an Independent Risk Marker for Chronic Lung Allograft Dysfunction (CLAD)
Purpose: CLAD is a significant challenge in lung transplantation with limited early diagnostic tools. We previously demonstrated hyaluronan (HA), an extracellular matrix molecule associated with pulmonary inflammation and fibrosis, accumulates in the BALF of lung recipients with CLAD. We aimed to determine if early posttransplant elevations in BALF HA inform future CLAD risk and identify a replicable BALF HA threshold for risk prediction. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , J. Weber, M. Neely, F. Kelly, A. Nagler, L. Eason, P. McArthur, J. Belperio, M. Budev, J. Reynolds, P. Shah, L. Singer, L. Snyder, S. Palmer, J. Todd Source Type: research
An Exploration of Gene Expression Patterns Underlying Restrictive and Obstructive Chronic Lung Allograft Dysfunction (CLAD) Phenotypes Using Non-Negative Matrix Factorization
Purpose: Pathways active in CLAD subtypes, bronchiolitis obliterans syndrome (BOS) and restrictive allograft syndrome (RAS), remain poorly understood. We aimed to uncover CLAD phenotype-specific mechanisms using the comprehensive and unsupervised non-negative matrix factorization (NMF)-based clustering algorithm applied to bulk RNA sequencing data from human CLAD lungs. We hypothesized this would uncover differential transcriptomic signatures related to epithelial, pro-fibrotic, and immune pathways in RAS and BOS. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , J. Allen, G. Berra, R. Ghany, S. Keshavjee, G. Wilson, J. Yeung, S. Juvet, T. Martinu Source Type: research
